Cargando…
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
Lung cancer leads cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC), the most prevalent subtype of this recalcitrant cancer, is usually diagnosed at advanced stages, and available systemic therapies are mostly palliative. The probing of the NSCLC kinome has identified numerous n...
Autores principales: | Jorge, S.E.D.C., Kobayashi, S.S., Costa, D.B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Divulgação Científica
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230282/ https://www.ncbi.nlm.nih.gov/pubmed/25296354 http://dx.doi.org/10.1590/1414-431X20144099 |
Ejemplares similares
-
Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
por: Kobayashi, Kunihiko, et al.
Publicado: (2013) -
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
por: Khaddour, Karam, et al.
Publicado: (2021) -
Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma
por: Makinoshima, Hideki, et al.
Publicado: (2014) -
Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
por: Gini, Beatrice, et al.
Publicado: (2020) -
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
por: O’Leary, Connor, et al.
Publicado: (2020)